AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28432746 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine 100 U and lixisenatide)
Number of subjects: 1170
Study 28432746 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 1170
Study 25808269 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121
Study 25808269 — intervention group
Group type: COMPARATOR
Intervention: Individual adolescent focused therapy (AFT)
Number of subjects: 121
Study 23558841 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal approach
Number of subjects: 82
Study 23558841 — intervention group
Group type: COMPARATOR
Intervention: Tunnel vision approach
Number of subjects: 82
Study 21774289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide and gentamicin injections followed by topical tobramycin eye drops four times daily for one week (IC TA group, n=30)
Number of subjects: 60
Study 21774289 — intervention group
Group type: COMPARATOR
Intervention: Topical dexamethasone-tobramycin combination eyedrops four times daily until no inflammation was seen (Topical group, n=30)
Number of subjects: 60
Study 19326828 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week health promotion course
Number of subjects: 0
Study 16674744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 32
Study 16674744 — intervention group
Group type: COMPARATOR
Intervention: 2% CHX gel
Number of subjects: 32
Study 15296549 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA (metaphonological abilities development), 91 students
Number of subjects: 202
Study 15296549 — intervention group
Group type: EXPERIMENTAL
Intervention: DLS (language skills development through active story listening), 65 students
Number of subjects: 202
Study 15296549 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical first-grade methods), 46 students
Number of subjects: 202
Study 11730823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic-androgenic steroids (AAS)
Number of subjects: 26
Study 11730823 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (GnRH agonist)
Number of subjects: 26
Study 11730823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 26
Study 9229097 — intervention group
Group type: EXPERIMENTAL
Intervention: SICU care after major plastic/reconstructive procedures
Number of subjects: 42
Study 9229097 — intervention group
Group type: COMPARATOR
Intervention: Control group (random cohort)
Number of subjects: 42
Study 9229097 — intervention group
Group type: COMPARATOR
Intervention: PACU care for at least 24 hours of perioperative monitoring
Number of subjects: 42
Study 8431119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 278
Study 8431119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine hydrochloride bolus
Number of subjects: 278
Study 8431119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine continuous infusion
Number of subjects: 278
Study 3582476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (25 mg)
Number of subjects: 7
Study 3582476 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 7
Study 3582476 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (100 mg)
Number of subjects: 7
Study 3582476 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (500 and 1000 mg)
Number of subjects: 7
Study 3582476 — intervention group
Group type: COMPARATOR
Intervention: Meptazinol (100 and 200 mg)
Number of subjects: 7
Study 3582476 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (25 and 50 mg)
Number of subjects: 7
Study 3582476 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 and 650 mg)
Number of subjects: 7
Study 3582476 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine (10 mg)
Number of subjects: 7
Study 31558010 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxelan® monotherapy (1 suppository at bedtime for 1 month)
Number of subjects: 30
Study 29153295 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL of 37.5 mg ropivacaine plus 40 mg methylprednisolone (active group, n=49)
Number of subjects: 97
Study 29153295 — intervention group
Group type: COMPARATOR
Intervention: 15 mL of saline (placebo group, n=48)
Number of subjects: 97
Study 27714870 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based educational intervention to reduce verbal bullying; details on dosage and duration not specified.
Number of subjects: 0
Study 26831423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bentonite cream
Number of subjects: 100
Study 26831423 — intervention group
Group type: COMPARATOR
Intervention: Calendula cream
Number of subjects: 100
Study 23680182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐2·5 GUM
Number of subjects: 50
Study 23680182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐5 GUM
Number of subjects: 50
Study 23680182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐5 LP GUM
Number of subjects: 50
Study 23680182 — intervention group
Group type: COMPARATOR
Intervention: Std GUM
Number of subjects: 50
Study 20609727 — intervention group
Group type: EXPERIMENTAL
Intervention: OR template
Number of subjects: 20
Study 20609727 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 20
Study 18516654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary tibial cutting guide (Group 1, n=31)
Number of subjects: 70
Study 18516654 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary tibial cutting guide (Group 2, n=39)
Number of subjects: 70
Study 17115273 — intervention group
Group type: EXPERIMENTAL
Intervention: WBOAS-augmented PT/OT care
Number of subjects: 0
Study 17115273 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 0
Study 15571955 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 309
Study 15571955 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy
Number of subjects: 309
Study 11693688 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized sleep (10 hr.)
Number of subjects: 82
Study 11693688 — intervention group
Group type: COMPARATOR
Intervention: Restricted sleep (4 hr.)
Number of subjects: 82
Study 9418839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 20
Study 9418839 — intervention group
Group type: COMPARATOR
Intervention: Humulin R
Number of subjects: 20
Study 9418839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin (open label continuation)
Number of subjects: 20
Study 9418839 — intervention group
Group type: COMPARATOR
Intervention: Humulin R (open label continuation)
Number of subjects: 20
Study 8292434 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser hemorrhoidectomy
Number of subjects: 35
Study 8292434 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 35
Study 8292434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 3549807 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil
Number of subjects: 150
Study 3549807 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil
Number of subjects: 150
Study 3549807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 3549807 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil
Number of subjects: 150
Study 3549807 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% minoxidil
Number of subjects: 150
Study 3549807 — intervention group
Group type: COMPARATOR
Intervention: Placebo to 3% minoxidil
Number of subjects: 150
Study 3549807 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (2% minoxidil, 3% minoxidil, placebo to 3% minoxidil)
Number of subjects: 150
Study 30654844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina
Number of subjects: 356
Study 30654844 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese massage
Number of subjects: 356
Study 29908389 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction tool based on well-established risk factors (number of previous depressive episodes, residual depressive symptoms, severity of the last depressive episode, treatment)
Number of subjects: 444
Study 29908389 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of the prediction tool
Number of subjects: 444
Study 26867060 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20-40 mg/Amlodipine 5-10 mg
Number of subjects: 260
Study 26867060 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 4-8 mg/Amlodipine 5-10 mg
Number of subjects: 260
Study 24330482 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 58
Study 24330482 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 58
Study 22578513 — intervention group
Group type: EXPERIMENTAL
Intervention: Production (PR) procedures
Number of subjects: 14
Study 22578513 — intervention group
Group type: COMPARATOR
Intervention: Estimation (EST) procedures
Number of subjects: 14
Study 19904596 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 36
Study 19904596 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 17874207 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine (detailed dosage not specified)
Number of subjects: 328
Study 17874207 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 328
Study 15503124 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 rpm
Number of subjects: 14
Study 15503124 — intervention group
Group type: COMPARATOR
Intervention: 80 rpm
Number of subjects: 14
Study 15503124 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 rpm
Number of subjects: 14
Study 15503124 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 rpm
Number of subjects: 14
Study 15503124 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely Chosen Cadence (FCC)
Number of subjects: 14
Study 11994249 — intervention group
Group type: EXPERIMENTAL
Intervention: JTT-705 900 mg
Number of subjects: 198
Study 11939055 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (1 mg sodium selenite, one time only)
Number of subjects: 2
Study 11939055 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 2
Study 7613531 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogen therapy
Number of subjects: 550
Study 7613531 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 550
Study 2167107 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg
Number of subjects: 4
Study 2167107 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 4
Study 2167107 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 4
Study 2167107 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 0 mg (placebo)
Number of subjects: 4
Study 1256690 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphthalone
Number of subjects: 10
Study 1256690 — intervention group
Group type: COMPARATOR
Intervention: Indomethacine
Number of subjects: 10
Study 30879735 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free beer with modified carbohydrate composition (16.5 g/day isomaltulose and 5.28 g/day resistant maltodextrin)
Number of subjects: 41
Study 30879735 — intervention group
Group type: COMPARATOR
Intervention: Regular alcohol-free beer
Number of subjects: 41
Study 30879735 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free beer with modified carbohydrate composition
Number of subjects: 41
Study 28118833 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D (utility)
Number of subjects: 488
Study 28118833 — intervention group
Group type: EXPERIMENTAL
Intervention: MHQ
Number of subjects: 488
Study 28118833 — intervention group
Group type: EXPERIMENTAL
Intervention: Various PROMs
Number of subjects: 488
Study 26100349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 26100349 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 0
Study 23414499 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Hispanic Blacks
Number of subjects: 2063
Study 23414499 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Hispanic Whites
Number of subjects: 2063
Study 23414499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 2063
Study 23414499 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Hispanic Blacks and Whites
Number of subjects: 2063
Study 23414499 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Hispanic Whites and Hispanics
Number of subjects: 2063
Study 21525247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) (500 mg/d DHA + 150 mg/d EPA)
Number of subjects: 0
Study 21525247 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐methyltetrahydrofolate (400 μg/d)
Number of subjects: 0
Study 21525247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fish oil and 5‐methyltetrahydrofolate
Number of subjects: 0
Study 21525247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19257818 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg) administered within 90 days after surgical repair of an osteoporotic hip fracture
Number of subjects: 2127
Study 19257818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 17875874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air cooling during and 30 seconds before and after laser irradiation
Number of subjects: 23
Study 17875874 — intervention group
Group type: COMPARATOR
Intervention: No cooling (control)
Number of subjects: 23
Study 17875874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cooled and uncooled sides
Number of subjects: 23
Study 15459137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg b.i.d. by inhalation and 100 microg intranasally once daily)
Number of subjects: 15
Study 15459137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (intranasally)
Number of subjects: 15
Study 15459137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15459137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (inhalation)
Number of subjects: 15
Study 11564611 — intervention group
Group type: EXPERIMENTAL
Intervention: Real water treatment units (WTUs) designed to remove viruses, bacteria, and protozoa.
Number of subjects: 600
Study 11564611 — intervention group
Group type: COMPARATOR
Intervention: Sham water treatment units (WTUs).
Number of subjects: 600
Study 9587120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral blood flow analysis assessed by color Doppler ultrasound
Number of subjects: 66
Study 7820981 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin, 100 micrograms subcutaneously at induction of anaesthesia and 8 hourly for 48 h
Number of subjects: 18
Study 7820981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3078526 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 5 micrograms/kg
Number of subjects: 45
Study 3078526 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 1 microgram/kg
Number of subjects: 45
Study 3078526 — intervention group
Group type: COMPARATOR
Intervention: no analgesic supplement
Number of subjects: 45
Study 4998492 — intervention group
Group type: EXPERIMENTAL
Intervention: Scribner shunts
Number of subjects: 0
Study 4998492 — intervention group
Group type: COMPARATOR
Intervention: Brescia fistulae
Number of subjects: 0
Study 31644691 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) treatment, 20 one-hour sessions
Number of subjects: 26
Study 31644691 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) treatment
Number of subjects: 26
Study 31644691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study 29041563 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlens arrays (MLA) with varying spatial coherence and randomization parameters
Number of subjects: 0
Study 26082390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab plus mitoxantrone and prednisone (MP)
Number of subjects: 132
Study 26082390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus mitoxantrone and prednisone (MP)
Number of subjects: 132
Study 26082390 — intervention group
Group type: COMPARATOR
Intervention: Control (historical control)
Number of subjects: 132
Study 24156549 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted tailored implementation strategy including a specific web page and workshops for family physicians and nurses.
Number of subjects: 0
Study 24156549 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation (Control group).
Number of subjects: 0
Study 21357311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive-pressure breathing
Number of subjects: 135
Study 21357311 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 135
Study 19327776 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment apolipoproteins A1 and B
Number of subjects: 0
Study 19327776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering treatment
Number of subjects: 0
Study 19327776 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose simvastatin
Number of subjects: 0
Study 17608061 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture with indwelling fixed needles (points lung, shenmen, forehead and hip)
Number of subjects: 64
Study 17608061 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (4 non-acupuncture points on the helix)
Number of subjects: 64
Study 15330021 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee replacement
Number of subjects: 6
Study 15330021 — intervention group
Group type: COMPARATOR
Intervention: Conventional jig-assisted total knee replacement
Number of subjects: 6
Study 11495621 — intervention group
Group type: COMPARATOR
Intervention: Studies published during 1966-1990
Number of subjects: 593
Study 11495621 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies published during 1991-2000
Number of subjects: 593
Study 9432318 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg tid and omeprazole 40 mg/day for 2 weeks, followed by omeprazole (20 or 40 mg daily) for 2 additional weeks.
Number of subjects: 0
Study 8496462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon-alpha (1 million U, injected three times weekly for 6 weeks)
Number of subjects: 14
Study 8496462 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo control)
Number of subjects: 14
Study 3103950 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA) (n = 77)
Number of subjects: 290
Study 3103950 — intervention group
Group type: COMPARATOR
Intervention: streptokinase (SK) (n = 68)
Number of subjects: 290
Study 3103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rt‐PA and SK
Number of subjects: 290
Study 28872700 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy followed by esophagogastroduodenoscopy (EGD)
Number of subjects: 120
Study 28872700 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD) followed by colonoscopy
Number of subjects: 120
Study 27815148 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (monthly cash transfer conditional on school attendance ≥80% of school days per month)
Number of subjects: 2537
Study 27815148 — intervention group
Group type: COMPARATOR
Intervention: No cash transfer (control group)
Number of subjects: 2537
Study 27815148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (overall comparison)
Number of subjects: 2537
Study 24096730 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap and water plus hand sanitizer (Experimental Group)
Number of subjects: 1341
Study 24096730 — intervention group
Group type: COMPARATOR
Intervention: Usual handwashing procedure (Control Group)
Number of subjects: 1341
Study 23179896 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 10 mg (up-titrated to 20 mg or 40 mg if needed)
Number of subjects: 1453
Study 23179896 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 2.5 mg (up-titrated to 5 mg or 10 mg if needed)
Number of subjects: 1453
Study 23179896 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (in patients with valid ambulatory BP recordings and metabolic syndrome)
Number of subjects: 1453
Study 23179896 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (in patients with valid ambulatory BP recordings and metabolic syndrome)
Number of subjects: 1453
Study 23179896 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 1453
Study 23179896 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 1453
Study 20557330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 300
Study 20557330 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 300
Study 19011368 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive program
Number of subjects: 120
Study 19011368 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic intervention
Number of subjects: 120
Study 19011368 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 16183007 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention to improve cancer pain management
Number of subjects: 157
Study 16183007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain characteristics (severity, duration, meaning of pain, perceived availability and efficacy of pain relief)
Number of subjects: 157
Study 16183007 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 157
Study 14974812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM) with enamel matrix proteins (EMP)
Number of subjects: 60
Study 14974812 — intervention group
Group type: COMPARATOR
Intervention: Simplified papilla preservation (SPP) flap with enamel matrix proteins (EMP)
Number of subjects: 60